|
LEA3D offers a facility to screen or to design small molecules
The user first builds a scoring function and then, at the second step, either uploads a library of molecules or selects the de novo drug design option
The FDA-approved drug structure data set can be selected at the step 2
References:
- LEA3D: A Computer-Aided Ligand Design for Structure-Based Drug Design, Douguet D., Munier-Lehmann H., Labesse G. and Pochet S, J. Med. Chem., 2005, 48, 2457-2468. doi: 10.1021/jm0492296
- e-LEA3D: a computational-aided drug design web server, Douguet D., Nucleic Acids Res., 2010, 38, Suppl:W615-21. doi: 10.1093/nar/gkq322
- LEA (Ligand by Evolutionary Algorithm): A genetic algorithm for the automated generation of small organic molecules: Drug design using an evolutionary algorithm, Douguet D., Thoreau E. and Grassy G., J. Comput.-Aided Mol. Design, 2000, 14, 449-466. doi: 10.1023/A:1008108423895
- The source code of the core is available on GitHub LEA3D repository.
|